Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series

Müller, Daniel A; Beltrami, Giovanni; Scoccianti, Guido; Campanacci, Domenico A; Franchi, Alessandro; Capanna, Rodolfo

Abstract: BACKGROUND The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of combining denosumab with surgical treatment and highlights possible changes for the oncologic surgeon in daily practice. METHODS A total of 91 patients were treated surgically for giant cell tumor of bone between 2010 and 2014 in an institution, whereas 25 patients of the total additionally received denosumab and were part of this study. The average age of the patients was 35 years. Eleven patients received denosumab pre- and postoperatively, whereas with 14 patients, the denosumab treatment was applied either before (7 patients) or after (7 patients) the surgery. The average preoperative therapy duration was 3.9 months and the postoperative therapy 6 months by default. RESULTS Sixteen patients presented a large tumor extension necessitating a resection of the involved bone or joint. In 10 of these patients, the indication for a resection procedure was abandoned due to the preoperative denosumab treatment and a curettage was performed. In the remaining six cases, the surgical indication was not changed despite the denosumab treatment, and two of them needed a joint replacement after the tumor resection. Also with patients treated with curettage, denosumab seems to facilitate the procedure as a new peripheral bone rim around the tumor was built, though a histologic analysis reveals viable tumor cells persisting in the denosumab-induced bone formation. After an average follow-up of 23 months, one histologically proven local recurrence occurred, necessitating a second curettage. A second patient showed a lesion in the postoperative imaging highly suspicious for local relapse which remained stable under further denosumab treatment. No adverse effect of the denosumab medication was observed in this study. CONCLUSIONS Denosumab can be a help to the oncologic surgeon by reconstituting a peripheral rim and switching the stage from aggressive to active or latent disease. But as tumor cells remain in the new-formed bone, the surgical technique of curettage has to be changed from gentle to more aggressive to avoid higher local recurrence rates.

DOI: https://doi.org/10.1186/s12957-016-1034-y

Originally published at:
Müller, Daniel A; Beltrami, Giovanni; Scoccianti, Guido; Campanacci, Domenico A; Franchi, Alessandro; Capanna, Rodolfo (2016). Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series. World Journal of Surgical Oncology, 14:281. DOI: https://doi.org/10.1186/s12957-016-1034-y
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series

Daniel A. Müller1, Giovanni Beltrami2, Guido Scoccianti2, Domenico A. Campanacci3, Alessandro Franchi4 and Rodolfo Capanna2

Abstract

Background: The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of combining denosumab with surgical treatment and highlights possible changes for the oncologic surgeon in daily practice.

Methods: A total of 91 patients were treated surgically for giant cell tumor of bone between 2010 and 2014 in an institution, whereas 25 patients of the total additionally received denosumab and were part of this study. The average age of the patients was 35 years. Eleven patients received denosumab pre- and postoperatively, whereas with 14 patients, the denosumab treatment was applied either before (7 patients) or after (7 patients) the surgery. The average preoperative therapy duration was 3.9 months and the postoperative therapy 6 months by default.

Results: Sixteen patients presented a large tumor extension necessitating a resection of the involved bone or joint. In 10 of these patients, the indication for a resection procedure was abandoned due to the preoperative denosumab treatment and a curettage was performed. In the remaining six cases, the surgical indication was not changed despite the denosumab treatment, and two of them needed a joint replacement after the tumor resection. Also with patients treated with curettage, denosumab seems to facilitate the procedure as a new peripheral bone rim around the tumor was built, though a histologic analysis reveals viable tumor cells persisting in the denosumab-induced bone formation. After an average follow-up of 23 months, one histologically proven local recurrence occurred, necessitating a second curettage. A second patient showed a lesion in the postoperative imaging highly suspicious for local relapse which remained stable under further denosumab treatment. No adverse effect of the denosumab medication was observed in this study.

Conclusions: Denosumab can be a help to the oncologic surgeon by reconstituting a peripheral rim and switching the stage from aggressive to active or latent disease. But as tumor cells remain in the new-formed bone, the surgical technique of curettage has to be changed from gentle to more aggressive to avoid higher local recurrence rates.

Keywords: Giant cell tumor, Bone, Denosumab, Benign tumor, Adjuvant treatment, Surgery
Background
Giant cell tumor of bone (GCTB) is a primary benign lesion with local aggressive behavior, affecting usually young adults. GCTB accounts for approximately 5% of all bone tumors and 20% of all benign tumors with a slight preference for females [1, 2].

The disease commonly presents as an epiphysial, lytic lesion most often localized in the distal femur, proximal tibia, and distal radius [1]. It is characterized by progressive growth and bone lysis with relatively well-defined margins. The cortex of the involved bone is usually thinned, often expanded, and sometimes breached with or without soft tissue expansion [3].

The clinical course is unpredictable if untreated, because of possible mechanical load failure and joint function compromise. By 1–4% of all patients affected by GCTB pulmonary metastases are detected even when the histologic appearance remains benign [4].

The tumor tissue consists of two different cell populations: First, the multinucleated giant cells, which are diffusely distributed throughout the tumor mass and which are responsible for the disease typical massive bone absorption [5]. Second, mononucleated fibrous cells are found with an oval or fusiform shape, which not only present a proliferative activity and neoplastic cytogenetic anomalies but also promote the formation and activation of the giant cells from precursor cells [5].

Surgical removal of the lesion remains to date the only curative treatment for GCTB [6]. Most of the times, a local curettage is performed, followed by stuffing the bone defect with bone cement or bone graft and prophylactic internal fixation. But in some advanced GCTB, the tumor lesion is too extended for a simple curettage, necessitating an en bloc excision of the involved bone and joint [7]. Even if different surgical techniques are available for the following reconstruction, significant functional impairment and surgical morbidity cannot be completely avoided [8].

Denosumab, a monoclonal antibody inhibiting the receptor activator of nuclear factor-kappa β ligand (RANKL), first introduced for the treatment of severe osteoporosis [9], has been recently approved for the application in patients with GCTB [10].

RANKL is an essential cytokine for the formation, function, and survival of osteoclasts [11]. Denosumab inhibits the interaction between RANKL, continuously expressed by the tumor stromal cells, and its receptor (RANK) on the osteoclasts. In this manner, the progression of bone resorption and osteolytic tumor expansion is reversibly blocked [12]. These molecular changes correlated with new bone formation and increased radiologic density on CT scans [13].

In the current practice, denosumab is provided to patients with GCTB that is classified as “unresectable” or to avoid large surgical resection with severe morbidity. As denosumab is a relatively new treatment for GCTB, the literature is still sparse regarding indication, as well as timing and duration of the drug application.

This study focuses on the risks and benefits of denosumab for the treating oncologic surgeon. In contrast to the previous studies [13, 14], all included patients underwent a surgical procedure already indicated at diagnosis, giving denosumab the role of an adjuvant treatment comparable to radiation therapy in soft tissue sarcomas.

Methods
Patients
A total of 91 patients underwent surgery for GCTB between 2010 and 2014 in one institution. Of them, 25 patients (26.6%) received denosumab either preoperative, postoperative, or at both stages and were included in the study. The prospective gathered patient’s data was retrospectively reviewed. Both indication and sequence of surgery and denosumab treatment were individually discussed and defined in a multidisciplinary board. Preoperative denosumab treatment was applied in the following situations:

- Large tumor extension necessitating a bone resection
- Local advanced disease with a high risk for local recurrence after curettage
- Anatomic locations with impending pathologic fractures, for example, pelvis, femoral head, and foot

If the surgical removal of the tumor was difficult to achieve in these situations and some residual disease was suspected, the denosumab treatment was continued postoperatively. In some cases, the preoperative imaging did not correspond to the intraoperative findings. According to the radiologic findings, the tumor was assessed as easily removable and no neo-adjuvant treatment was performed. But the intraoperative situus revealed a much more advanced disease than expected. These patients received postoperative denosumab only for minimizing the risk of local recurrence and stabilization of the clinical course.

Denosumab treatment was not considered if the GCTB was easily accessible by simple curettage. Distinct contraindications for denosumab application included skeletal immaturity, anamnestic active dental or jaw problems, and pregnancy.

The average age of the patients was 35.4 years (range 15–72 years). The tumor was found most frequently in the distal femur (seven cases; 29.2%), followed by the distal and proximal tibia with three cases each (12.5%). A more detailed overview of the patients is given in Table 1.
Treatment
The diagnosis of GCTB was always confirmed by a CT-guided core needle biopsy. The preoperative tumor extension was assessed by conventional X-ray, CT, and MRI scans. In all the included cases, the tumor was classified as stage 3 according to the Enneking classification for benign bone tumors [15].

Patients received open-label subcutaneous denosumab 120 mg every 4 weeks, with additional doses administered on days 8 and 15 during the first month of therapy only. For patients who received also a postoperative treatment, denosumab therapy continued for six additional doses after surgery.

Planned surgical procedures were recorded before the application of denosumab and compared to the actual performed surgery. Procedure selection and timing were based on serial review of imaging studies and individual assessment by the oncologic surgeon.

Postoperatively, patients were examined clinically and radiologically every 3 months during the first 2 years and every 6 months after 2 years.

Results
The enrolled patients were observed for a mean follow-up of 23 months (9–49 months).

Denosumab treatment
The denosumab therapy was applied in 11 patients (44 %) both pre- and postoperatively, whereas in 7 patients (2 × 28 %), the treatment was either pre- or postoperative. The mean preoperative therapy duration was 3.9 months (range 3–6 months) and the postoperative therapy 6 months by default.

No adverse effect or any complication due to the denosumab treatment was observed. Four cases (16 %) showed local progression of disease under denosumab therapy and were therefore classified as “non-responder”.

Surgery
In 16 patients (64 %), a resection of the involved bone or joint was indicated as the tumor extension was too large for a curettage procedure. After the preoperative denosumab treatment, the decision of the surgical procedure

| Table 1 Patient demographics |
|-----------------------------|
| Patient Gender | Age (years) | Follow-up (months) | Localization | Denosumab preoperative | Denosumab postoperative |
|-----------------|------------|-------------------|--------------|------------------------|------------------------|
| 1 F 30 36       | Distal humerus Yes Yes |
| 2 M 31 43       | Femoral head No Yes |
| 3 F 65 21       | Distal tibia Yes Yes |
| 4 M 51 33       | Distal radius No Yes |
| 5 M 72 32       | Distal femur No Yes |
| 6 M 32 17       | Distal femur Yes Yes |
| 7 F 16 33       | Patella Yes No |
| 8 F 19 41       | Distal tibia Yes No |
| 9 M 62 31       | Metacarpal bone Yes No |
| 10 F 21 31      | Proximal tibia Yes No |
| 11 F 15 49      | Proximal tibia Yes Yes |
| 12 M 62 27      | Distal radius Yes Yes |
| 13 M 29 19      | Distal femur Yes Yes |
| 14 F 40 17      | Sacrum Yes Yes |
| 15 M 27 21      | Proximal tibia No Yes |
| 16 F 27 14      | Proximal fibula Yes Yes |
| 17 M 27 14      | Proximal radius Yes Yes |
| 18 F 44 15      | Proximal fibula Yes No |
| 19 F 30 13      | Distal femur Yes Yes |
| 20 M 31 13      | Distal femur Yes No |
| 21 M 25 9       | Distal tibia Yes Yes |
| 22 M 46 14      | Distal femur No Yes |
| 23 M 22 10      | Calcaneus No Yes |
| 24 F 37 10      | Distal femur No Yes |
| 25 F 23 13      | Iliac wing Yes No |
was changed in 10 out of these 16 cases and the indication for a resection was abandoned. During the preoperative denosumab therapy, repeated MRI and CT scans were performed. The surgical indication was changed if a relevant shrinkage of the lesion was observed or the rim showed advanced ossifications. In either way, the stability of the involved bone was improved, and a curettage was possible now. All these cases were therefore described as “surgical downstaging” (Fig. 1).

In six cases (24%), the indication for resection was not changed despite denosumab treatment. But in four patients, the resection was less invasive and easier to perform according to the surgeon’s appreciation, even if the extension into the soft tissues was advanced in these cases. Denosumab has led to an ossification of the soft tissue mass, facilitating the en bloc resection. Increased bone density simplifies the intraoperative manipulation and prevents an unintended burst of the tumor.

In four out of six resections, no further reconstruction was needed, as the resected bone was not mechanically relevant for weight-bearing. In the remaining two cases, one affecting the proximal radius and one the proximal tibia, an allograft prosthetic composite was done to restore the joint function (Fig. 2).

A total of 19 patients (76%) underwent a local, surgical aggressive curettage: After the removal of the tumor mass with spoons, the residual rim was removed with a high-speed burr and the cavity was instilled with liquid phenol. In 18 out of 19 patients, an additional cryotherapy was applied: First, a sterile thermoconducting gel, routinely used in urology and gynecology, was inserted in the cavity. Afterwards, several probes were placed inside the liquid gel. The temperature at the tip of the probe was successively decreased by the help of Argon to −100 °C, creating a controlled “iceball” around the probe (Fig. 3). After 5 min, the temperature was raised again to 35 °C. This cycle was repeated two times, changing the position of the probes in each cycle.

For nine patients (36%), a curettage was indicated already before beginning the denosumab therapy. With seven patients (28%), the surgeon rated the performed curettage as less extensive than planned on the primary radiographs.

More details about the surgical treatment of every case are given in Table 2.

Local recurrence

One histologically proven local recurrence was observed (4%). The patient (case nr. 7) underwent a curettage of the patella, and a local relapse occurred 7 months postoperatively. The relapse was found in the periphery of the patella towards the joint surface, which raises the question if the curettage was done properly. After a second curettage, the patient was disease free at the last follow-up. Patient nr. 1 showed radiologic changes 6 months after curettage at the distal humerus, highly suspicious for local recurrence. The patient preferred the continuation of the denosumab treatment instead of a revision surgery. At the last follow-up, no clinical or radiological progression was seen.

Histologic changes

In all the cases who received preoperative denosumab treatment, the microscopic morphologic appearance of the intraoperative specimen was completely different compared to the preoperative biopsy sample (Fig. 4). The osteoclast-like giant cells disappeared almost completely. The residual tumor consisted mainly of spindle cells without any atypia, often organized in a storiform pattern. Besides the cellular component, regions of collagen matrix formation were seen. The collagen presented a diffuse or a honeycomb/trabecular archetype fusing with osteoid formation.
These two different zones were not distributed randomly but arranged in a centrifugal pattern, with cellular areas in the center and matrix forming areas at the periphery of the tumor.

In 11 of the patients (45.8 %), a detailed genotype analysis and immunohistochemical staining was performed [16]. From a surgical point of view, the most interesting findings were a significant reduction in microvascular density of the post-denosumab specimen and a significant overall decrease of the cellular proliferation index [16].

Discussion

GCTB is a rare, epidemiologic, and clinically well-defined bone tumor with relevant local aggressiveness for which in the last 30 years, the surgical resection or curettage was the only treatment option. No real alternative existed for locally advanced disease or for difficult anatomic localizations not susceptible for surgery.

The recent introduction of denosumab has completely changed the approach and clinical course of the disease. Denosumab permits with high reliability and low risks the blockade of local tumor growth and enables less-invasive surgical procedures [13].

This study focuses on the benefits and risks of combining a surgical treatment of GCTB with neo-adjuvant or adjuvant denosumab application. It is retrospective and the patients were not randomized for treatment, so selecting bias may exist. The indication for denosumab, thus indirectly the inclusion in the study, was decided by a multidisciplinary board. As a consequence, only locally aggressive, extended tumor lesions were enrolled. Our results are therefore not applicable for latent (grade 1) or active (grade 2) lesion in GCTB.

We observed in 40 % a surgical downstaging attributable to the denosumab treatment, decreasing the percentage of large resections from 64 to 24 %. The percentage of patients who underwent a less-invasive surgical procedure as planned at the study entry was the same as previously reported [14] in a multicenter study.

But also, patients who experienced no surgical downstaging benefit from denosumab treatment as the resection procedure is facilitated. The decrease of microvascular density reduces the intraoperative bleeding, and the increased bone density simplifies the intraoperative manipulation and prevents an unintended burst of the tumor.

Interestingly, our local recurrence rate however is slightly lower compared to other patients treated with denosumab and surgery (8 vs. 15 %) [14]. We assume the type of curettage and the use of local intraoperative adjuvants as the possible reasons. Histologically, the giant
cells disappeared almost completely, but the stromal cells persisted, which represent the true neoplastic cells [16]. Although they are fewer and less proliferating, they are still alive and likely able to reactivate after the end of the therapy. After the complete simple curettage, a peripheral rim of new-formed bone is present with multiple lacunae inside where tumor cells remain ("honey comb").

In contrary to the soft tumor mass in untreated GCTB, the denosumab-induced changes necessitate a much more aggressive curettage technique. We highly suggest the use of a high-speed burr and local adjuvants to reach the remaining tumor in the re-ossificated zones. The intraoperative use of phenol, peroxide water, or liquid nitrogen is described to improve local control in curettage procedures [7, 17–20]. We preferred the application of cryotherapy as the penetration depth in the surrounding bone is probably the best [19]. Liquid nitrogen has the same effect as our performed technique with probes. However, the probes create a predictable zone of ice around the tip, reducing the risks and complications for the soft tissue close to the lesion.

Table 2  Treatment overview

| Patient | Drug response | Surgical downstaging | Performed surgery | Filling after curettage | Local recurrence |
|---------|--------------|----------------------|-------------------|------------------------|-----------------|
| 1       | Yes          | Yes                  | Curettage + plate fixation | Cement               | (Yes)           |
| 2       | Yes          | No                   | Curettage          | Bone allograft        | No              |
| 3       | Yes          | Yes                  | Curettage + plate fixation | Cement               | No              |
| 4       | Yes          | No                   | Curettage          | Cement                | No              |
| 5       | Yes          | No                   | Curettage + plate fixation | Cement               | No              |
| 6       | Yes          | No                   | Soft tissue excision | N/A                   | No              |
| 7       | Yes          | No                   | Curettage          | Cement                | Yes             |
| 8       | Yes          | Yes                  | Curettage          | Cement + bone allograft | No              |
| 9       | Yes          | No                   | Curettage          | Bone allograft        | No              |
| 10      | No           | No                   | Resection and APC  | N/A                   | No              |
| 11      | Yes          | Yes                  | Curettage          | Bone allograft        | No              |
| 12      | Yes          | Yes                  | Curettage + plate fixation | Cement               | No              |
| 13      | Yes          | Yes                  | Curettage + plate fixation | Cement               | No              |
| 14      | Yes          | Yes                  | Curettage          | Bone allograft        | No              |
| 15      | No           | No                   | Curettage + screw  | Cement                | No              |
| 16      | Yes          | No                   | Bone resection     | N/A                   | No              |
| 17      | No           | No                   | Resection and APC  | N/A                   | No              |
| 18      | Yes          | No                   | Bone resection     | N/A                   | No              |
| 19      | Yes          | No                   | Bone resection     | N/A                   | No              |
| 20      | Yes          | Yes                  | Curettage + plate fixation | Cement + bone allograft | No              |
| 21      | Yes          | Yes                  | Curettage          | Bone allograft        | No              |
| 22      | Yes          | No                   | Curettage + plate fixation | Cement               | No              |
| 23      | Yes          | No                   | Curettage          | Bone allograft        | No              |
| 24      | No           | No                   | Curettage + plate fixation | Cement               | No              |
| 25      | Yes          | Yes                  | Curettage          | Bone allograft        | No              |

APC: allograft prosthetic composite, N/A: not applicable

Fig. 4  Histologic appearance after denosumab treatment. Histologic appearance of denosumab-treated giant cell tumor of bone. The residual tumor is composed of bland spindle cells organized in short fascicles, associated with collagen matrix production. No osteoclast-like multinucleated giant cells are present.
No new safety risks were observed in this case series concerning the denosumab treatment, as no adverse effect occurred. But osteonecrosis of the jaw and hypocalcemia, although at low rates, are known serious side effects [21]. A total of four patients (16 %) were classified as non-responder as the tumor was progressive under denosumab treatment. In all these cases, the surgical indication had not to be changed, and the patients had no negative consequences. But there is an undeniable risk to transform an acute treatable disease in a chronic disease with possible worsening of the local situation. Until now, there are no predisposing or risk factors known for anticipating a denosumab treatment failure.

Conclusions
Denosumab seems to be an important help to the oncologic surgeon by reconstituting a peripheral rim, reducing intraoperative bleeding, and switching the stage from aggressive to active or latent disease. All these factors lead to a surgical down staging facilitating the procedure. But as tumor cells remain in the new-formed bone, the surgical technique of curettage has to be changed from gentle to more aggressive using high-speed burr and local adjuvant.

Abbreviations
APC: Allograft prosthetic composite; GCTB: Giant cell tumor of bone; RANKL: Receptor activator of nuclear factor-kappa β ligand

Acknowledgements
None.

Funding
The authors, their immediate family, and any research foundation with which they are affiliated did not receive any financial payments or other benefits from any commercial entity related to the subject of this non-comment.

Availability of data and materials
All analyzed data of this study are included in this article. The anonymized clinical data is saved online using “organized lab” from LabArchives, LLC (Carlsbad, CA 92008, USA). The dataset supporting the conclusions of this article is available in the Clinical studies/GCTB_denosumab repository, doi: 10.6070/Y4Q4N45SN. The data is accessible via hyperlink: https://mynoteblock.labarchives.com/share/Danie%2520M%25C3%2581ller/MyNotebook/Giant%2520cell%2520tumour%2520of%2520bone%2520-–%2520treatment%2520failure%2520in%2520denosumab%2520treated%2520patients/4MjMuN9v5M38i58vOC90euImvTIEm9kZ8z7O5gxU4wMDM0DUjLQ=.

Authors’ contributions
DAM contributed to the conception and design, analysis and interpretation of the data, and drafting the manuscript. GS, DAC, and AF contributed to the data acquisition, and analysis and interpretation of the data. GB and RC contributed to the conception and design, acquisition of the data, analysis and interpretation of the data, and correction of the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All patients gave their informed consent for their participation in this study and consented to publishing the results by signing the institutional consent form.

Ethics approval and consent to participate
The work has been approved by the local ethical committee of the institution in which surgical procedures have taken place.

Author details
1 Department of Orthopedic Surgery, University Hospital Balgrist, Forchstrasse 340, 8008 Zürich, Switzerland. 2 Department of Orthopedic Oncology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Firenze, Italy. 3 Department of Traumatology and Orthopedic Surgery, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Firenze, Italy. 4 Division of Anatomic Pathology, Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy.

Received: 4 May 2016 Accepted: 25 October 2016

References
1. Picci PM, Manfrini M, Fabbrini N, Gambardelli M, Vanel D. Atlas of musculoskeletal tumors and tumortike lesions. 1 edn. Cham Heidelberg Dordrecht London New York: Springer International Publishing; 2014.
2. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009;21:338–44.
3. Reineck D, Kryiakos M, Greenway GD. Tumors and tumor-like lesions of bone: imaging and pathology of specific lesions. Diagnosis of bone and joint disorders. 3rd ed. Philadelphia: Saunders; 1995. p. 3628–3938.
4. Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br. 1998;80:43–7.
5. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013;52:238–46.
6. Skubitz KM. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol. 2014;15:507–18.
7. Szendroi I, Mignet D. Giant-cell tumour of bone. J Bone Joint Surg Br. 2004;86:965–12.
8. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–246.
9. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.
10. European Medicines Agency. Summary of product characteristics: Xgeva® (denosumab). 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed 27 Oct 2016.
11. Steensma MR, Tyler WK, Shaber AG, Goldring SR, Williams BO, et al. Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. PLoS One. 2013;8:e69101.
12. Kim Y, Nizami S, Goto H, Lee FY. Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor. Clin Orthop Surg. 2012;4:107–16.
13. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275–80.
14. Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015;22:2860–8.
15. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.
16. Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69:240–7.
17. Gaston CJ, Bhumbra R, Watanuki M, Abudzi AT, Carter SR, Jeys LM, et al. Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone? J Bone Joint Surg Br. 2011;93:1665–9.
18. Gortzak Y, Kandel R, Deheshi B, Werier J, Turcotte RE, Ferguson PC, et al. An in vitro study. J Bone Joint Surg Br. 2010;92:1475–9.
19. Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Chawla S, Hershaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletal maturity addescents with giant cell tumour of bone: interim analysis of an open-label, parallel-phase, 2 phase study. Lancet Oncol. 2013;14:901–8.